SCIENCE@home

Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

Sakina A. Plumber,Tiffany Tate,H. Al-Ahmadie,Xiao Chen,W. Choi,Merve Basar,Chao Lu,A. Viny,E. Batourina,Jiaqi Li,Kristjan H. Gretarsson,Besmira Alija,A. Molotkov,Gregory Wiessner,Byron H Lee,J. McKiernan,D. McConkey,Colin P.N. Dinney,Bogdan A. Czerniak,Cathy L. Mendelsohn

Published 2024 in Nature Communications

ABSTRACT

Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-basal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable expression in BASQ tumors, we tested the effects of rosiglitazone, Pparg agonist, in a mouse model of BASQ BC. We find that rosiglitazone reduces proliferation while treatment with rosiglitazone plus trametinib, a MEK inhibitor, induces apoptosis and reduces tumor volume by 91% after 1 month. Rosiglitazone and trametinib also induce a shift from BASQ to luminal differentiation in tumors, which our analysis suggests is mediated by retinoid signaling, a pathway known to drive the luminal differentiation program. Our data suggest that rosiglitazone, trametinib, and retinoids, which are all FDA approved, may be clinically active in BASQ tumors in patients. New treatments are needed for muscle invasive bladder cancers. Here, the authors show that combined Pparg activation and MEK inhibition using FDA approved drugs shrinks tumor volume and induces a Basal/Squamous-to-Luminal shift in the urothelium as well as in invading tumors.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-86 of 86 references · Page 1 of 1

CITED BY

Showing 1-20 of 20 citing papers · Page 1 of 1